Axogen

Axogen has priced an upsized public offering of common stock, aiming to raise approximately $124 million in gross proceeds. The company intends to use these funds to pay off its term loan facility, bolster working capital, and support future growth initiatives. This move follows recent strong revenue reports and FDA approval for its AVANCE product, positioning Axogen for continued expansion in the peripheral nerve repair market.